DBVT (DBV Technologies) Accumulated Depreciation: $-23.50 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DBVT DBV Technologies SA DBVT
31 GF Score
Price $13.63
! 1 Warning Sign
View Full Analysis

What is DBV Technologies Accumulated Depreciation?

DBV Technologies DBVT -1.73% 31 Accumulated Depreciation is $-23.50 Mil as of Jun. 2026. GuruFocus rates DBVT with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

DBV Technologies's quarterly accumulated depreciation declined from Dec. 2025 ($-22.88 Mil) to Mar. 2026 ($0.00 Mil) but then increased from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($-23.50 Mil).

DBV Technologies's annual accumulated depreciation declined from Dec. 2023 ($-18.95 Mil) to Dec. 2024 ($-17.53 Mil) but then increased from Dec. 2024 ($-17.53 Mil) to Dec. 2025 ($-22.88 Mil).

DBV Technologies Accumulated Depreciation Related Terms

DBV Technologies Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for DBV Technologies's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DBV Technologies Accumulated Depreciation Chart

DBV Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.80 -14.79 -18.95 -17.53 -22.88

DBV Technologies Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -22.88 0.00 -23.50
DBVT
31GF Score
DBV Technologies SA DBVT
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DBV Technologies Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-23.50 Mil mean?
DBV Technologies (DBVT) has a Accumulated Depreciation of $-23.50 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on DBV Technologies and its competitors.
Is DBV Technologies' Accumulated Depreciation too high?
DBV Technologies' current Accumulated Depreciation is $-23.50 Mil. Overall, DBV Technologies has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DBV Technologies' Accumulated Depreciation compare to VRTX and REGN?
DBV Technologies' Accumulated Depreciation of $-23.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on DBV Technologies and its competitors. DBV Technologies's current Accumulated Depreciation is $-23.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DBV Technologies stock overvalued right now?
DBV Technologies (DBVT) has a current Accumulated Depreciation of $-23.50 Mil. The current Accumulated Depreciation is $-23.50 Mil. DBV Technologies' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For DBV Technologies (DBVT), the current Accumulated Depreciation is $-23.50 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DBV Technologies Business Description

Address 107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
31GF Score

Get the complete analysis for DBVT

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.63
Price